We are in the process of updating this page. Please bear with us...
Diagnostics
ILD
A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre. (2016)
Bagpipe lung; A New Type of Interstitial Lung Disease? (2016)
Bagpipe lung; A New Type of Interstitial Lung Disease? (2016)
IPF
Peripheral eosinophilia in Idiopathic Pulmonary Fibrosis - Are there clinical implications? A retrospective cohort study of patients commencing antifibrotic therapy (2020)
What can we learn from the idiopathic pulmonary fibrosis registries? (2018)
The impact of a network based approach on lung function and symptom duration at diagnosis in idiopathic pulmonary fibrosis (2018)
Idiopathic Pulmonary Fibrosis: An Overview (2018)
Idiopathic pulmonary fibrosis: a clinical update (2018)
Idiopathic Pulmonary Fibrosis: A holistic approach to disease management in the anti-fibrotic age (2017)
Managing Idiopathic Pulmonary Fibrosis. Which drug for which patient (2017)
IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe. Advances in Therapy (2015)
New Data in IPF: A Pivotal Change in the future of IPF Treatment (2014)
What can we learn from the idiopathic pulmonary fibrosis registries? (2018)
The impact of a network based approach on lung function and symptom duration at diagnosis in idiopathic pulmonary fibrosis (2018)
Idiopathic Pulmonary Fibrosis: An Overview (2018)
Idiopathic pulmonary fibrosis: a clinical update (2018)
Idiopathic Pulmonary Fibrosis: A holistic approach to disease management in the anti-fibrotic age (2017)
Managing Idiopathic Pulmonary Fibrosis. Which drug for which patient (2017)
IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe. Advances in Therapy (2015)
New Data in IPF: A Pivotal Change in the future of IPF Treatment (2014)
Sarcoidosis
Hypersensitivity Pneumonitis
Antifibrotics
No relevant pharmacokinetic interaction between nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from a drug-drug interaction study (2018)
Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience (2018)
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres (2017)
Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. (2016)
Nintedanib for treating idiopathic pulmonary fibrosis (2016)
Real World Experiences: pirfenidone is well tolerated in patients with idiopathis pulmonary fibrosis (2014)
Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience (2018)
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres (2017)
Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. (2016)
Nintedanib for treating idiopathic pulmonary fibrosis (2016)
Real World Experiences: pirfenidone is well tolerated in patients with idiopathis pulmonary fibrosis (2014)
| New data in IPF: a pivotal change in the future of IPF treatment (2014) |
| Real world experiences with pirfenidone (2013) |
The role of bronchoalveolar lavage and its quality in the diagnosis of interstitial lung disease.
Idiopathic Pulmonary Fibrosis: “Lost in the system” in the North West of England?
Do Antifibrotics Impact on Lung Transplantation Outcomes in Idiopathic Pulmonary Fibrosis?
Can baseline physiological tests help predict the outcome of hypoxic challenge testing (HCT) in Interstitial Lung Disease (ILD)?
ATS 2017.
Clinical Experience with Nintedanib for Idiopathic Pulmonary Fibrosis in 3 UK Tertiary Interstitial Lung Disease Centres. Hannah Toellner1, W. Beswick2, M.G. Crooks2, C. Donaldson3, I. Forrest3, S.P. Hart2, C. Leonard4, M. Major2, A.J. Simpson3 and N. Chaudhuri4.
5 Years of Real World Pirfenidone Experience. Gareth Hughes, Colm Leonard, Nazia Chaudhuri
BTS 2017.
The role of bronchoalveolar lavage and its quality in the diagnosis of interstitial lung disease.
Idiopathic Pulmonary Fibrosis: “Lost in the system” in the North West of England?
Do Antifibrotics Impact on Lung Transplantation Outcomes in Idiopathic Pulmonary Fibrosis?
Can baseline physiological tests help predict the outcome of hypoxic challenge testing (HCT) in Interstitial Lung Disease (ILD)?
ATS 2017. Clinical Experience with Nintedanib for Idiopathic Pulmonary Fibrosis in 3 UK Tertiary Interstitial Lung Disease Centres. Hannah Toellner1, W. Beswick2, M.G. Crooks2, C. Donaldson3, I. Forrest3, S.P. Hart2, C. Leonard4, M. Major2, A.J. Simpson3 and N. Chaudhuri4.
ATS 2017. 5 Years of Real World Pirfenidone Experience. Gareth Hughes, Colm Leonard, Nazia Chaudhuri
ERS 2016. Clinical Experience with Nintedanib for IPF in 3 UK tertiary referral centres Hannah Toellner1, W. Beswick2, M.G. Crooks2, C. Donaldson3, I. Forrest3, S.P. Hart2, C. Leonard4, M. Major2, A.J. Simpson3 and N. Chaudhuri4.
Hanley, M; Leonard, C; Chaudhuri, N; P28 Real World MDT Diagnosis of Idiopathic Pulmonary FibrosisThorax70Suppl 3A90-A902015BMJ Publishing Group Ltd and British Thoracic Society
Gudur, Sharada; Newton, Pippa; Leonard, Colm; Chaudhuri, Nazia; Lymphopoenia and pneumocystis jiroveci (PCP) prophylaxis experience in non-specific interstitial pneumonitis (NSIP)European Respiratory Journal44Suppl 58P7602014Eur Respiratory Soc
Nuttall, E; Crooks, M; Gudur, S; Leonard, C; Major, C; Hart, S; Chaudhuri, N; P6 Early Clinical Experience With Nintedanib–a two centre reviewThorax70Suppl 3A77-A772015BMJ Publishing Group Ltd and British Thoracic Society
Chaudhuri, N; Leonard, CT; M263 A Quarter Of Ipf Patients Not Eligible For Pirfenidone Treatment Due To The Nice Criteria Significantly Decline Over TimeThorax69Suppl 2A218-A2182014BMJ Publishing Group Ltd and British Thoracic Society
Chaudhuri, N; Leonard, CT; M264 Health And Economic Impact Of Prescribing PirfenidoneThorax69Suppl 2A218-A2192014BMJ Publishing Group Ltd and British Thoracic Society
Leonard, Colm; Chaudhuri, N; Real World Experiences: Pirfenidone Is Well Tolerated In Patients With Idiopathic Pulmonary FibrosisA38. DIAMONDS ARE FOREVER BUT NEW TREATMENTS FOR INTERSTITIAL LUNG DISEASE CAN'T WAITA1424-A14242014Am Thoracic Soc
Parfrey, H; Chaudhuri, N; Gibbons, MA; Anning, L; Balkin, M; Cooper, S; Dew, R; Maher, TM; P280 Extended Clinical Experience With Pirfenidone During A Named Patient Programme For Idiopathic Pulmonary Fibrosis (ipf): Interim ResultsThorax69Suppl 2A196-A1962014BMJ Publishing Group Ltd and British Thoracic Society
Hughes, Gareth; Toellner, Hannah; Morris, Helen; Leonard, Colm; Chaudhuri, Nazia; Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary FibrosisJournal of Clinical Medicine59782016Multidisciplinary Digital Publishing Institute
Chaudhuri, Nazia; Spencer, Lisa; Leonard, Colm; Evolution of an interstitial lung disease MDT: 5.5 years of dataEuropean Respiratory Journal44Suppl 58P34982014Eur Respiratory Soc
Gudur, S; Nuttall, E; Harris, C; Chaudhuri, N; Leonard, C; Muldoon, E; SARCOIDOSIS AND CO-EXISTENT ASPERGILLUS LUNG DISEASETHORAX70A92-A932015BMJ PUBLISHING GROUP BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
Nasr, R; Kausar, I; Chaudhuri, N; S10 Cost Burden Of N-acetylcysteine (nac) In Adult Patients With Idiopathic Pulmonary FibrosisThorax69Suppl 2A8-A82014BMJ Publishing Group Ltd and British Thoracic Society
Chaudhuri, Nazia; Duck, Annette; Holme, Jayne; Frank, Rebecca; Leonard, Colm; Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPFEuropean Respiratory Journal42Suppl 57P23332013Eur Respiratory Soc
Whyte, Moira; Chaudhuri, Nazia; Burge, Geraldine; Howes, Timothy; Respiratory2014
Chaudhuri, N; Duck, A; Greaves, M; Leonard, CT; S13 Sole use of forced vital capacity as per national institute of health and care excellence criteria disadvantage 2 in 5 people with idiopathic pulmonary fibrosisThorax68Suppl 3A10-A102013BMJ Publishing Group Ltd and British Thoracic Society
Partfrey, H; Chaudhuri, N; Gibbons, MA; Anning, L; Balkin, M; Cooper, S; Dew, R; Maher, TM; EXTENDED CLINICAL EXPERIENCE WITH PIRFENIDONE DURING A NAMED PATIENT PROGRAMME FOR IDIOPATHIC PULMONARY FIBROSIS (IPF): INTERIM RESULTSTHORAX69A196-A1962014BMJ PUBLISHING GROUP BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
Wright, A; Helm, J; Spencer, L; Leonard, C; Bishop, P; Greaves, M; Chaudhuri, N; S12 Interstitial lung disease multidisciplinary discussion: six years of data from a tertiary serviceThorax68Suppl 3A9-A102013BMJ Publishing Group Ltd and British Thoracic Society
| ats_2014_pirf.ppt |
| 5 Years of Real World Pirfenidone Experience. Gareth Hughes, Colm Leonard, Nazia Chaudhuri.ppt |
| thorax-2016-king-thoraxjnl-2016-208751.pdf |
| Nintedanib for treating idiopathic pulmonary fibrosisBritish Journal of Healthcare Management2.pdf |
| Hanley, M; Leonard, C; Chaudhuri, N; P28 Real World MDT Diagnosis of Idiopathic Pulmonary FibrosisThorax70Suppl 3A90-A902015BMJ Publishing Group Ltd and British Thoracic Societyl.pdf |
| Gudur, S; Nuttall, E; Harris, C; Chaudhuri, N; Leonard, C; Muldoon, E; SARCOIDOSIS AND CO-EXISTENT ASPERGILLUS LUNG DISEASETHORAX70A92-A932015BMJ.ppt |
| duck_et_al_2015_adv_ther_ipf_care.pdf |
| Chaudhuri, N., Duck, A., Frank, R., Holme, J., & Leonard, C. (2014). Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.Respiratory medicine,l.pdf |
| Hughes, Gareth; Toellner, Hannah; Morris, Helen; Leonard, Colm; Chaudhuri, Nazia; Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary FibrosisJournal of Clinical Medicine.pdf |
| Chaudhuri, N. (2014). New Data in IPF: A Pivotal Change in the future of IPF Treatment.Respiratory Disease in Practise. 20-11-14.pdf |
| Shaw J, Leonard C, Chaudhuri N. Feather bedding as a cause of hypersensitivity pneumonitis. QJM.pdf |
| Hayton C and Chaudhuri N. Managing Idiopathic Pulmonary Fibrosis. Which drug for which patient. Drugs Ageing.pdf |
| a_review_of_the_multidisciplinary_diagnosis_of_interstitial_lung_diseases__a_retrospective_analysis_in_a_single_uk_specialist_centre.pdf |
